The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Increasing the domestic production of essential medicines is one of the few issues that Republicans and Democrats both support. Since the onset of the COVID pandemic, more than 50 bills have been introduced in Congress, many bipartisan, to encourage and support this production. Both the Trump and Biden administrations also presented strategies to enhance the […]
AAM Statement on Biden-Harris Administration’s 100-Day Supply Chain Review
WASHINGTON DC (June 8, 2021) – The Association for Accessible Medicines (AAM) supports the Biden-Harris administration’s 100-day review of the pharmaceutical and active pharmaceutical ingredient (API) supply chains. The Biden-Harris administration has produced a thoughtful plan to strengthen the security of the U.S. pharmaceutical supply chain that recognizes the importance of engaging with our allies […]
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry. […]
The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds
The U.S. generics and biosimilars industry, makers of 90% of our nation’s prescription medicines, has a plan to “#SecureOurMeds.” We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through COVID and beyond. Learn more about our path forward at: https://www.secureourmeds.org/
AAM Statement on President Biden’s Supply Chain Executive Order
WASHINGTON, DC (February 25, 2021) — The Association for Accessible Medicines strongly supports President Biden’s America’s Supply Chains Executive Order as an important step toward strengthening the U.S. pharmaceutical supply chain and improving patient access to lower-cost generic and biosimilar medicines. The Executive Order is a prudent, considered approach to fully understanding the scope and […]
AAM Releases Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain
WASHINGTON, DC (April 30, 2020) — The Association for Accessible Medicines today released “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain,” a six-element framework that lays out concrete actions that the federal government could take to ensure that U.S. patients and the U.S. health care system have access to a secure and […]
AAM’s Recommendations to #SecureOurMeds
Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription. In these unprecedented […]
Generics: The Bridge to A Vaccine
I am honored to be named CEO of the Association for Accessible Medicines. Representing the industry responsible for 90 percent of the prescriptions filled in the U.S. provides an unparalleled opportunity to positively impact the lives of hundreds of millions of American patients who rely on generic and biosimilar medicines to maintain and improve their […]
The Generic and Biosimilar Industry Has a Plan to Secure Our Medicines
The U.S. generics and biosimilars industry, makers of 90% of our nation’s prescription medicines, has a plan to “#SecureOurMeds.” We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through #COVID and beyond. Find out more about our path forward: https://accessiblemeds.org/blueprint
COVID-19 Response: Steve Giuli at Apotex
Steve Giuli works at Apotex as Vice President, Government Affairs & Trade Relations. Steve is proud to be a part of the generic drug industry that saves and improves patients’ lives. AAM is recognizing dedicated people like Steve and his peers across the generics and biosimilars industry who show up each day for U.S. patients. […]
How “Stocking the Pantry” Protects the Supply Chain
AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain and documents like it provide lawmakers with the ingredients for achieving a legislative goal. Since we published this reliable resource at the end of April, senators, representatives and their staff have sought out the expertise of AAM staff regarding supply issues affecting our […]
Strengthening the U.S. Pharmaceutical Supply Chain: What We Know—and What We Don’t
Last week the U.S. Department of Health and Human Services announced a grant worth up to $812 million for a public-private partnership to manufacture COVID-related medicines in the United States. In the rush to reclaim some of the U.S. manufacturing of medicines that has moved across the globe over the past two decades, journalists and […]
